What does Crovalimab (Piasky) do in plain English—and how does it work inside your body?
Crovalimab is an FDA-regulated Complement C5 Inhibitor (RxNorm RxCUI 2686626). Mechanistically, 12.1 Mechanism of Action Crovalimab-akkz is a monoclonal antibody that specifically binds with high affinity to the complement protein C5, inhibiting its cleavage into C5a and C5b, preventing the formation of the membrane attack complex (MAC). Crovalimab-akkz inhibits terminal complement-mediated intravascular hemolysis in patients with PNH. [1][2].
When your doctor writes a prescription for Crovalimab (RxNorm RxCUI 2686626, also dispensed under brand names including Piasky), the goal is to target the root physiological pathway driving your condition rather than just masking surface symptoms [1]. According to the official FDA DailyMed package insert, 12.1 Mechanism of Action Crovalimab-akkz is a monoclonal antibody that specifically binds with high affinity to the complement protein C5, inhibiting its cleavage into C5a and C5b, preventing the formation of the membrane attack complex (MAC). Crovalimab-akkz inhibits terminal complement-mediated intravascular hemolysis in patients with PNH. [2].
Across real-world patient logs on dotMD (93% positive worth-it rating), patients do best when they understand both what the medication is doing on day 1 and how long it takes to reach steady-state protection [3].
Check the imprint code on your Crovalimab tablet bottle and confirm with your pharmacist that it matches your prescribed strength (340 mg/2mL Injection, Solution, Therapeutic monitoring titration for Crovalimab (complement c5 inhibitor)).